

E2 mRNA, L1 mRNA, and L2 mRNA; and

determining a ratio of E6 and/or E7 mRNA to L1 and/or L2 and/or E2 mRNA, wherein any ratio of greater than 4 is indicative of HPV-induced cancer.

12. A method of diagnosing the risk or onset of HPV-induced cancer in a patient infected with HPV comprising the steps of:

- quantifying a group 1 and a group 2 and/or a group 3 HPV mRNA from a sample collected from said patient; and
- determining a ratio of group 1 mRNA level to group 2 and/or group 3 mRNA level wherein any ratio of greater than 4 is indicative of high risk or onset of HPV-induced cancer.

REMARKS

Applicants respectfully request favorable consideration of the present application and claims. The newly added claims are supported by the original specification and do not introduce any new matter. Early and favorable action by the Examiner is earnestly solicited.

No additional fee is believed to be necessary.

The Commissioner is hereby authorized to charge any additional fees which may be required for this amendment, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2629-4005US4.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition and for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 13-4500, Order No. 2629-4005US4. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Date: October 4, 2001

By: Darryl H. Steensma
Darryl H. Steensma
Registration No. 43,155

MORGAN & FINNEGAN, L.L.P.
345 Park Ave
New York, NY 10154-0053
(212)-758-4800 Telephone
(212)-751-6849 Facsimile